Gross Profit Analysis: Comparing Bio-Techne Corporation and Perrigo Company plc

Biotech vs. Pharma: A Decade of Gross Profit Trends

__timestampBio-Techne CorporationPerrigo Company plc
Wednesday, January 1, 20142514110001447700000
Thursday, January 1, 20153072770001712400000
Friday, January 1, 20163366590002051800000
Sunday, January 1, 20173745410001979500000
Monday, January 1, 20184321430001831500000
Tuesday, January 1, 20194734910001773300000
Wednesday, January 1, 20204831940001815200000
Friday, January 1, 20216328500001416200000
Saturday, January 1, 20227564960001455400000
Sunday, January 1, 20237698150001680400000
Monday, January 1, 2024769725000
Loading chart...

Unlocking the unknown

Gross Profit Trends in the Biotech and Pharmaceutical Sectors

In the ever-evolving landscape of the biotech and pharmaceutical industries, understanding financial health is crucial. Bio-Techne Corporation and Perrigo Company plc, two giants in their respective fields, have shown distinct trends in gross profit over the past decade. From 2014 to 2023, Bio-Techne's gross profit surged by over 200%, reflecting its robust growth and strategic market positioning. In contrast, Perrigo's gross profit, while consistently higher, exhibited a more modest increase of around 16% during the same period. Notably, Bio-Techne's gross profit peaked in 2023, while Perrigo experienced a dip in 2021, highlighting potential challenges. The data for 2024 is incomplete, suggesting a need for further analysis. These insights underscore the dynamic nature of these industries and the importance of financial metrics in assessing company performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025